	Application No.	Applicant(s)
Notice of Allowability	09/777,566	SHORT ET AL.
	Examiner	Art Unit
	Delia M. Ramirez	1652
	Della W. Nathirez	1032
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.31	6 (OR REMAINS) CLOSED in) or other appropriate communication. This application is su	this application. If not included nication will be mailed in due course: THIS
1. This communication is responsive to <u>1/22/2007</u> .		
2. \boxtimes The allowed claim(s) is/are $\underline{1-13,16-18,20-33,35,36,38-43}$,45,46,82-88 and 92-98.	
3. Acknowledgment is made of a claim for foreign priority u	nder 35 U.S.C. § 119(a)-(d) o	r (f).
a) All b) Some* c) None of the:		•
 Certified copies of the priority documents hav 	e been received.	
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDON! THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") mu	st be submitted.	·
(a) ☐ including changes required by the Notice of Draftsper	son's Patent Drawing Review	(PTO-948) attached
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date	_•	
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment or	in the Office action of
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	<u>. –</u>	
1. Notice of References Cited (PTO-892)	<u></u>	ormal Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		mmary (PTO-413), ⁄lail Date
3. ⊠ Information Disclosure Statements (PTO/SB/08),		Amendment/Comment
Paper No./Mail Date 6/30/2006 4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's S	Statement of Reasons for Allowance
of Biological Material	9.	

DETAILED ACTION

Status of the Application

Claims 1-13, 16-33, 35-36, 38-43, 45-46, 81-88, 92-98 are pending.

Amendment of claims 1-2, 8, 10-12, 16, 20, 35-36, 38-43, 46, 81-88, 92-94, 97-98 as submitted in a communication filed on 1/22/2007 is acknowledged.

In a telephone conversation with Mr. Gregory Einhorn on 2/9/2007, an agreement was reached to amend claims 8-9, 35-36, 38-43, 45-46, 82-88, 92-94, 97-98 and cancel claims 19 (no longer referring to a signal peptide as amended by the examiner) and 81 (exact duplicate of claim 46) to place the application in condition for allowance.

Information Disclosure Statement

1. The supplementary partial European search report for EP 02 74 4174 cited in the IDS filed on 6/30/2006 as reference # 3 has been considered by the Examiner.

Examiner's Amendment

- 2. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
- 3. Authorization for this Examiner's amendment was given in a telephone interview with Mr. Gregory Einhorn on 2/9/2007.
- 4. Please cancel claims 19 and 81.
- 5. Please replace claims 8-9, 35-36, 38-43, 45-46, 82-88, 92-94, 97-98 as follows:

Art Unit: 1652

8. The expression system of claim 1, wherein the heterologous amino acid sequence encodes a transit peptide.

- 9. The expression system of claim 1, wherein said heterologous signal sequence encodes a pathogenesis-related (PR) protein PR-S signal peptide from tobacco.
- 35. A vector comprising a nucleic acid
 - (i) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (ii) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
 - (iii) encoding a polypeptide (A) comprising the amino acid sequence of SEQ ID NO:2 and lacking a homologous signal sequence, or (B) comprising the amino acid sequence of (A) and further comprising a heterologous signal sequence;
 - (iv) encoding a polypeptide (A) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and lacking a homologous signal sequence, or (B) comprising the amino acid sequence of (A) and further comprising a heterologous signal sequence;
 - (v) encoding a polypeptide comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous nucleotide sequence; or
 - (vi) completely complementary to any of the nucleic acids of (i)-(v).
- 36. An isolated cell comprising a vector comprising a nucleic acid
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;

- (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
- (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 38. A cloning vector comprising a nucleic acid
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

- (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 39. An expression vector comprising a nucleic acid
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
 - (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;

Art Unit: 1652

(iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;

(v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;

- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 40. A bacterial vector comprising a nucleic acid
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
 - (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
 - (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;

Art Unit: 1652

(vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or

Page 7

(B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a

heterologous signal sequence;

(vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a

heterologous nucleotide sequence;

(viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide

sequence encoding a heterologous amino acid sequence; or

(ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii),

or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide

of (iv), (v), (vi) or (viii).

41. A plasmid comprising a nucleic acid

(i) comprising the nucleotide sequence of SEQ ID NO:1;

(ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to

1296;

(iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence

encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and

further comprising a nucleotide sequence encoding a heterologous signal sequence;

(iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;

(v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from

amino acid residue 1 to 432;

(vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or

(B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a

heterologous signal sequence;

Art Unit: 1652

- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 42. A viral particle comprising a nucleic acid
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
 - (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
 - (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
 - (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
 - (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
 - (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;

Art Unit: 1652

(viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or

Page 9

(ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).

43. A phage comprising a nucleic acid

- (i) comprising the nucleotide sequence of SEQ ID NO:1;
- (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
- (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or

Art Unit: 1652

Page 10

- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 45. A recombinant expression system comprising a nucleic acid encoding a phytase enzyme
 - (i) having (A) the amino acid sequence of SEQ ID NO:2 lacking a homologous signal sequence, or (B) the amino acid sequence of (A) further comprising a heterologous signal sequence; or
 - (ii) having (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 lacking a homologous signal sequence, or (B) the amino acid sequence of (A) further comprising a heterologous signal sequence.
- 46. A method for making a phytase in a cell, wherein the phytase is encoded by an exogenous nucleic acid, comprising culturing the cell under conditions wherein the phytase is expressed,

wherein the exogenous nucleic acid

- (i) comprises the nucleotide sequence of SEQ ID NO:1;
- (ii) comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;
- (iii) comprises (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprises a nucleotide sequence encoding a heterologous signal sequence; or (iv) comprises the nucleotide sequence of (i), (ii), or (iii) and a heterologous nucleotide sequence.

Art Unit: 1652

82. An expression system for making a polypeptide having phytase activity, comprising an isolated host cell and an exogenous nucleic acid, wherein the exogenous nucleic acid codes for the polypeptide having phytase activity, wherein the isolated host cell is capable of expressing the polypeptide, and the polypeptide having phytase activity

- (i) comprises the amino acid sequence of SEQ ID NO:2;
- (ii) comprises the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (iii) comprises (A) the amino acid sequence of (i) or (ii), wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) further comprising a heterologous signal sequence;
- (iv) comprises the amino acid sequence of (i), (ii) or (iii) and a heterologous amino acid sequence; or
- (v) comprises enzymatically active fragments of (i), (ii), (iii) or (iv).
- 83. A recombinant expression system comprising an isolated host cell comprising a variant nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid
 - (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;
 - (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;

Art Unit: 1652

(iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; (iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; or

Page 12

(v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asp and Gln, (e) an exchange of the basic residues Lys and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

Art Unit: 1652

84. An isolated prokaryotic cell comprising a variant nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid

- (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;
 - (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;
 - (iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; (iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal
 - (v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

sequence, or (B) the amino acid sequence of (A) and further comprising a

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asp and Gln, (e) an exchange of the basic residues Lys

heterologous signal sequence; or

Art Unit: 1652

and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

Page 14

- 85. A vector comprising a variant nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid
 - (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;
 - (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;
 - (iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence;

 (iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid
 - residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal

Art Unit: 1652

sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; or

(v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asn and Gln, (e) an exchange of the basic residues Lys and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

- 86. An isolated host cell comprising a vector comprising a variant nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid
 - (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;

- (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;
- (iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; (iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; or
- (v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asn and Gln, (e) an exchange of the basic residues Lys and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

Art Unit: 1652

wherein the nucleic acid encoding the polypeptide having phytase activity is operably linked to a transcriptional control sequence, and the amino acid sequence of the polypeptide having phytase activity has at least 95% sequence identity to SEQ ID NO:2.

- 87. An isolated host cell comprising a variant exogenous nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid
 - (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;

- (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;
- (iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence;
- (iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; or
- (v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

Art Unit: 1652

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asn and Gln, (e) an exchange of the basic residues Lys and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

- 88. An isolated eukaryotic cell comprising a variant nucleic acid encoding a polypeptide having phytase activity, wherein the variant nucleic acid
 - (1) encodes a polypeptide
 - (i) comprising the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution;
 - (ii) comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution;
 - (iii) comprising (A) the amino acid sequence of SEQ ID NO:2 and further comprising at least one conservative amino acid substitution, wherein the amino

Art Unit: 1652

acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence;

(iv) comprising (A) the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432 and further comprising at least one conservative amino acid substitution, wherein the amino acid sequence lacks a homologous signal sequence, or (B) the amino acid sequence of (A) and further comprising a heterologous signal sequence; or

Page 19

(v) comprising the amino acid sequence of (i), (ii), (iii), or (iv), and further comprising a heterologous amino acid sequence;

wherein the conservative amino acid substitution comprises (a) a replacement, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile, (b) an interchange of the hydroxyl residues Ser and Thr, (c) an exchange of the acidic residues Asp and Glu, (d) a substitution between the amide residues Asn and Gln, (e) an exchange of the basic residues Lys and Arg, (f) a replacement among the aromatic residues Phe, Tyr, or (g) any combination of (a), (b), (c), (d), (e), or (f);

- (2) encodes enzymatically active fragments of (1); or
- (3) comprises a nucleotide sequence that is the complete complement of the nucleotide sequence encoding the polypeptide of (1) or (2);

- 92. An expression system comprising a nucleic acid:
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;

Art Unit: 1652

(ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

- (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 93. An isolated, synthetic or recombinant nucleic acid:
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

Art Unit: 1652

(iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;

- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 94. A method for glycosylating a polypeptide comprising:
 - (a) providing a nucleic acid comprising a sequence encoding a polypeptide having phytase activity to a cell, wherein the nucleic acid has a nucleotide sequence:
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

Art Unit: 1652

(iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;

- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i),
- (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii); and
- (b) expressing the polypeptide in the cell wherein the cell is capable of glycosylating the polypeptide.
- 97. An isolated transformed cell or an isolated host cell comprising an exogenous nucleic acid:
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;

Art Unit: 1652

(ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

- (iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).
- 98. A vector comprising an exogenous nucleic acid:
 - (i) comprising the nucleotide sequence of SEQ ID NO:1;
 - (ii) comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide residue 1 to 1296;

Art Unit: 1652

(iii) comprising (A) the nucleotide sequence of (i) or (ii) lacking a nucleotide sequence encoding a homologous signal sequence, or (B) the nucleotide sequence of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence; (iv) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;

Page 24

- (iv) encouning a polypeptide comprising the animo acid sequence of 5DQ ib ivo.2,
- (v) encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid residue 1 to 432;
- (vi) encoding (A) the polypeptide of (iv) or (v) lacking a homologous signal sequence, or
- (B) the polypeptide of (A) and further comprising a nucleotide sequence encoding a heterologous signal sequence;
- (vii) comprising the nucleotide sequence of (i), (ii), or (iii) and further comprising a heterologous nucleotide sequence;
- (viii) encoding the polypeptide of (iv), (v), or (vi) and further comprising a nucleotide sequence encoding a heterologous amino acid sequence; or
- (ix) comprising a nucleotide sequence that is the complete complement of (i), (ii), (iii), or (vii), or the complete complement of the nucleotide sequence encoding the polypeptide of (iv), (v), (vi) or (viii).

Reasons for Allowance

6. The following is an Examiner's statement of reasons for allowance. Although the prior art discloses nucleic acids encoding phytases, the Examiner has found no teaching or suggestion in the prior art directed to the nucleic acid of SEQ ID NO:1 or nucleic acids encoding the polypeptide of SEQ ID NO:2. Therefore, claims 1-13, 16-18, 20-33, 35-36, 38-43, 45-46, 82-88, 92-98 directed to nucleic acids encoding the polypeptide of SEQ ID NO:2 and variants thereof as recited in the claims, host cells and vectors comprising said nucleic acids, a method to recombinantly produce the polypeptides encoded by

Art Unit: 1652

said nucleic acids, and a method for glycosylation of said polypeptides, are allowable over the prior art of record.

Conclusion

- 7. Claims 1-13, 16-18, 20-33, 35-36, 38-43, 45-46, 82-88, 92-98 are allowed.
- 8. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (571) 272-0938. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (571) 272-0928. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Delia M. Ramirez, Ph.D. Patent Examiner

Art Unit 1652

DR February 12, 2007

DELIA M. RAMIREZ, PH.D. PRIMARY EXAMINER